| Document |
Document Title |
|
WO/2024/085386A1 |
It has been identified that an alkynyl amino acid ester derivative preparation method using a photocatalytic reaction, according to the present invention, is simple and enables a linear, cyclic or chiral alkynyl amino acid ester derivati...
|
|
WO/2023/205233A1 |
Disclosed are compounds comprising chemically modified gamma-hydroxybutyrate (GHB) having the structure of Formula I, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at...
|
|
WO/2023/203297A1 |
The present invention relates to a method for preparing a lithium salt A comprising a step a) of bringing a lithium salt B, comprising at least one group –S(O)2-F, into contact with a compound C of formula (I) R-O-SiR1R2R3 in the prese...
|
|
WO/2023/205237A1 |
Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are...
|
|
WO/2023/135532A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at le...
|
|
WO/2023/123404A1 |
The present application discloses an industrial preparation method for acetoacetyl-N-sulfamate, the acetyl-N-sulfamate being used as an intermediate for synthesizing Acesulfame-K. The method comprises the following steps: step 1, dissolv...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/062653A1 |
Tthe present invention relates to novel herbicidal composition for protecting crops against weeds, undesired vegetation and grasses, and the corresponding methods of protection by application of the said composition. More, particularly, ...
|
|
WO/2023/041906A1 |
The invention relates to a compound of formula (I) comprising a mitochondrial targeting group linked to a group capable of releasing hydrogen sulphide for use in the treatment of the human or animal body or tissues and cells derived ther...
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/025854A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of said ...
|
|
WO/2023/014927A1 |
Disclosed herein are prodrugs of tapinarof and pharmaceutical formulations comprising tarpinarof, such as oral formulations. Further disclosed herein are methods for treating diseases and disorders of the gastrointestinal tract, skin, ey...
|
|
WO/2022/246870A1 |
A method for preparing an acetoacetamide-N-sulfonic acid triethylamine salt, the method comprising: an amination reaction step, involving: dissolving sulfamic acid in first dichloromethane to obtain a first reaction solution; dissolving ...
|
|
WO/2022/246871A1 |
A method for preparing an acetoacetamide-N-sulfonic acid triethylamine salt, the method comprising: dissolving sulfamic acid in first dichloromethane to prepare a first reaction solution; dissolving triethylamine in second dichloromethan...
|
|
WO/2022/201155A1 |
The present invention relates to a novel nitration process of 2- chloro -4- fluorobenzoic acid to 2-chloro-4- fluoro-5-nitrobenzoic acid, 2-chloro-4- f luoro-3 -nitrobenzoic acid and 3, 5-dinitro-2-chloro-4- fluorobenzoic acid; purifying...
|
|
WO/2022/196230A1 |
A lithium (N-carbonyl)sulfonamide compound represented by formula (I). In formula (I), R1 and R2 each represent a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, or an aryl group. L1 and L2 each represent a single bond...
|
|
WO/2022/164624A1 |
Biocide compositions comprising organic acyl halosulfonamides and methods for their use. The inherent stability provided by the molecular structure and enhanced penetration due to reductions in surface tension provides superior biocidal ...
|
|
WO/2022/165515A1 |
A process for producing a sulfamyl fluoride composition includes providing a solution comprising fluorosulfonic acid, urea and a solvent; reacting the solution at a reaction temperature from 80°C to about 170°C to produce a mixture inc...
|
|
WO/2022/158397A1 |
By means of a nonaqueous electrolyte that contains a compound represented in general formula (1), a solute, and a nonaqueous organic solvent, a nonaqueous electrolyte battery, and the compound represented in general formula (1), the pres...
|
|
WO/2022/149081A1 |
The present invention relates to an improved process for the preparation of an compound useful in the preparation of anti-androgenic compound.The present invention specifically relates to an improved process for the preparation of Tamsul...
|
|
WO/2022/036282A1 |
Inhibition of quorum sensing in Gram-negative bacteria, particularly strains of Vibrio, by certain compounds is disclosed. Compositions to treat bacterial infections and methods to treat such infections are also provided.
|
|
WO/2022/026789A1 |
Provided herein are compositions and methods for delivering pharmaceutical agents. In particular, provided herein are topical formulations of resatorvid for use in treating and preventing skin pathologies.
|
|
WO/2021/260232A1 |
The present invention concerns a method for the preparation of an alkyne-linker-payload construct of structure Q-L-C (O)-NR3-D (1), comprising reacting (i) an alkyne compound of structure Q-L- C(O)-X (2), wherein Q is an alkyne moiety se...
|
|
WO/2021/149776A1 |
The present disclosure provides, for example, compounds represented by general formula (6) [in the formula, X1, X2, X3, and X4 are each independently -CR2= or -N=; R2 is, for example, a halogen atom; R1 is, for example, -S(=O)2-NH-R8; R8...
|
|
WO/2021/060277A1 |
Provided are, inter alia, compounds useful as aminating agents capable of introducing an amino group protected by a deprotectable protecting group into a wide range of substates under relatively moderate conditions, an aminating agent ha...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2020/262648A1 |
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...
|
|
WO/2020/225569A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally s...
|
|
WO/2020/033715A1 |
Described herein are compositions and methods for treating cancer and autoimmune diseases.
|
|
WO/2019/188200A1 |
Provided is a production method for a lithium sulfamate. The production method for a lithium sulfamate is characterized by including a step (1) for reacting a compound (1) that is represented by general formula (1) (in which X is fluorin...
|
|
WO/2019/188207A1 |
Provided is an electrolyte solution that gives an electrochemical device having low resistance. This electrolyte solution is characterized by containing a compound represented by general formula (1) (In the formula, R101 and R102 are eac...
|
|
WO/2019/108824A1 |
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
|
WO/2019/088270A1 |
The present invention provides a compound that is highly safe and that is useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical compos...
|
|
WO/2019/047493A1 |
The present invention relates to an ionic liquid, a cation of which contains a hexafluoroisopropylsulfonic acid group. The ionic liquid provided by the present invention introduces a hexafluoroisopropylsulfonic acid group into a cationic...
|
|
WO/2019/027941A1 |
The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.
|
|
WO/2019/020016A1 |
Disclosed are a CA-4 antitumour drug, a synthesis method and the use thereof. The CA-4 antitumour drug introduces an alkoxy group or a fluorine-containing alkoxy group at the 4' position of a natural product, i.e., combretastatin, and ca...
|
|
WO/2019/004114A1 |
Provided is a production method for efficiently synthesizing a compound (1-2) which is an important intermediate in production of edoxaban. The method comprises dripping a compound (1-1) into a solution A that is obtained by causing a re...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/094233A2 |
Dimethylamine (Me2NH) is reacted with sulfuryl fluoride (S02F2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FS02NMe2), tetramethylsulfamide (S02(NMe2)2), or a combination thereof. A second phase, which may...
|
|
WO/2018/018091A1 |
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
|
|
WO/2017/217553A1 |
[Problem] To provide a novel agricultural chemical, and particularly an herbicide. [Solution] An oxime compound represented by formula (1) and an herbicide containing the same. (In formula (1): B represents B-1 or the like; Q represents ...
|
|
WO/2017/150903A1 |
The present invention relates to a pharmaceutical composition for treating or preventing CNS disorders containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the p...
|
|
WO/2017/140778A1 |
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently...
|
|
WO/2017/067837A1 |
Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, A, X and Y are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparatio...
|
|
WO/2017/059446A1 |
Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and meth...
|
|
WO/2017/031599A1 |
A quaternary ammonium sulfonamide compound of formula (I): wherein R = (II), C1-C3 linear or branched alkyl, R1 and R2 are the same or different and selected from C1 to C18 linear or branched alkyl, R3 and R4 are the same or different an...
|
|
WO/2016/172424A1 |
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)
|
|
WO/2016/128885A1 |
The present invention provides novel intermediates of cobicistat or a pharmaceutically acceptable salt thereof and a process for its preparation. The present invention also provides for the preparation of cobicistat or a pharmaceutically...
|
|
WO/2016/094897A1 |
Described herein are methods and compositions relating to the treatment of e.g., cancer, autoimmune disease, immune deficiency, and/or neurodegenerative disease. In some embodiments, the methods of treatment relate to administering a com...
|
|
WO/2016/082052A1 |
The invention relates to compounds derived from 2-phenyl-fluorosulfonamides of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and claims, and to a method for producing said compounds by preparing a solution with ...
|
